+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer

Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer

Journal of Oncology Pharmacy Practice 17(3): 292-294

We report a case of bevacizumab-associated hyperlipoproteinemia in a patient with advanced breast cancer. A 57-year-old woman with advanced invasive-ductal breast cancer was administered bevacizumab from March 2008 to February 2009. Pretreatment laboratory showed borderline hypercholesterolemia (5.1 mmol/L, 197 mg/dL) and normal triglycerides (1.3 mmol/L, 115 mg/dL). Three months on treatment with bevacizumab, both serum cholesterol (11.9 mmol/L, 460 mg/dL) and triglycerides (7.4 mmol/L, 655 mg/dL) increased substantially, and remained well above the normal range for a period of bevacizumab treatment. From March 2008 to August 2008, the patient also received anticancer treatment with liposomal doxorubicin that was stopped early due to hand-foot syndrome. No concurrent hyperlipidemic drugs have been taken by the patient at the time of bevacizumab treatment. In February 2009, bevacizumab was stopped and the patient went on to receive paclitaxel for hepatic tumor progression. By December 2009, both serum triglycerides (1.3 mmol/L, 115 mg/dL) and cholesterol (3.2 mmol/L, 123 mg/dL) had normalized. This is the first published case of bevacizumab-associated hyperlipoproteinemia. By applying the Naranjo ADR probability scales, at least a possible relationship between hyperlipoproteinemia type IIb and bevacizumab in this patient is supported by the data (Naranjo score 4). No hyperlipidemic drugs were given concurrently with bevacizumab, and the serum cholesterol and triglycerides decreased quickly after bevacizumab was discontinued. This study describes a case of bevacizumab-associated hyperlipidemia. Patients receiving bevacizumab should have their cholesterol and triglycerides checked for potential worsening.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036216102

Download citation: RISBibTeXText

PMID: 20667851

DOI: 10.1177/1078155210378912

Related references

Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers. American Journal of Surgery 198(4): 516-519, 2009

Poorly differentiated, invasive ductal breast cancer in a male patient. Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 58(12): 1016-1018, 2007

Trastuzumab in combination with bevacizumab in advanced breast cancer patient resistant to chemotherapy. Journal of Clinical Oncology 24(18_Suppl): 10762-10762, 2016

A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer. Breast Cancer 18(3): 226-230, 2011

Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not-otherwise-specified type. Breast 12(3): 172-178, 2003

Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Anticancer Research 25(3a): 1719-1723, 2005

Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population. Tumour Biology 36(8): 6113-6124, 2015

Effect of bevacizumab and chemotherapy on serum levels of sVCAM-1 in patient with inflammatory and locally advanced breast cancer. Journal of Clinical Oncology 23(16_Suppl): 611-611, 2016

Direct-Conversion Molecular Breast Imaging of Invasive Breast Cancer: Imaging Features, Extent of Invasive Disease, and Comparison Between Invasive Ductal and Lobular Histology. Ajr. American Journal of Roentgenology 205(3): W374-W381, 2015

Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. International Journal of Cancer 88(6): 907-913, 15 December, 2000

Expression of glycodelin protein and mRNA in human ductal breast cancer carcinoma in situ, invasive ductal carcinomas, their lymph node and distant metastases, and ductal carcinomas with recurrence. Oncology Reports 13(3): 413-419, 2005

Significant higher pathological response rate in invasive ductal vs lobular carcinomas after primary systemic chemotherapy with EC high dose in locally advanced breast cancer. Journal of Clinical Oncology 23(16_Suppl): 752-752, 2016

Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab. Aesthetic Plastic Surgery 34(6): 796-797, 2010

Risk factors for breast cancer death and subsequent invasive breast cancer after a primary ductal carcinoma in situ of the breast A population-based case-control study. Breast Cancer Research & Treatment 46(1): 44, 1997